Home » FDA Approves Puma’s Neratinib for HER2 Breast Cancer
FDA Approves Puma’s Neratinib for HER2 Breast Cancer
The FDA approved Puma Biotechnology’s Nerlynx (neratinib) for extended treatment of early-stage HER2-overexpressed breast cancer following a Herceptin-based therapy.
Approval was based on a Phase III randomized trial of Nerlynx following adjuvant Herceptin treatment.
The trial in more than 2,800 patients found treated patients had a rate of invasive disease-free survival of 94.2 percent after two years, compared to 91.9 percent with placebo.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May